If you are:
Only When Necessary:
FDB Contraindicated or Not Recommended: NO FDA CATEGORY; NOT RECOMMENDED ESPECIALLY IN 3RD TRIMESTER OR NEAR TERM
Only When Necessary: EVIDENCE FOR MALFORMATIONS; CAN REDUCE UTERINE BLOOD FLOW CAUSING FETAL HYPOXIA
FDB Only When Necessary: COMPATIBLE PER BRIGGS;OVERWHELMING HUMAN AND ANIMAL DATA SUGGESTS COMPATIBILITY
Absolute Contraindication: ONE REPORT OF METABOLIC ACIDOSIS; RISK OF REYE'S SYND IN VIRAL ILLNESS.
Precaution: INSUFFICIENT DATA AVAILABLE; MOLECULAR WT LOW ENOUGH FOR POSSIBLE EXCRETION
Precaution: ORAL BIOAVAILABILITY LOW; INFANT EXPOSURE MAY BE MINIMAL
Precaution: LOW MOLEC WT. POSSIBLE EXCRETION; NOT RECOM; MAY CAUSE PARADOXICAL EXCITATION
An adult over 60:
management or monitoring precaution: Gastrointestinal-Aspirin doses > 325 mg/day carry an increased risk for hemorrhage, GI bleed and ulceration. Lower doses preferred.
management or monitoring precaution: Cardiovascular-Elderly are more sensitive to tachycardia and hypertensive effects. May exacerbate symptomatic coronary insufficiency. Genitourinary-May cause urinary retention. Neuro/Psych-May worsen cognitive impairment in some elderly with dementia. Insomnia risk.
management or monitoring precaution: Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating antihistamine preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
Giving PE-DM-ASA/doxyla-PE-DM-ASA Tablet, Effervescent Sequential to a child under 12:
Severe Precaution: Not recommended age < 6 years without clinician consultation.
Contraindication: Do not use in pediatrics <6 years of age unless clinician consultation.
Contraindication: CNS excitation and convulsion risk in newborns. Not recommended age <2 years.
Severe Precaution: Reye syndrome risk with viral illness, fever, and/or flu symptoms.
Contraindication: Risk of CNS excitation. Do not use age <6 years without clinician consult.